Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia
Status:
Completed
Trial end date:
2019-05-22
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study was to establish a recommended phase 2 once daily
(QD) dose of dasatinib and to assess the efficacy of the investigational drug for relapsed or
refractory (resistant to previous treatment) leukemia in children and adolescents. The side
effects that this oral investigational drug may have in children, and the levels of the drug
in the blood, will be studied at different doses.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Innovative Therapies For Children with Cancer Consortium